Live
FierceBiotechGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failureFierceBiotechWith $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicinesLonza NewsFDA-backed drug project tests modeling to reduce some human studies - Stock TitanThermo FisherSaladax Biomedical and Thermo Fisher Scientific Partner on Global Distribution of Drug Monitoring Assays - Clinical Lab ProductsThermo FisherTD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Yahoo FinanceLonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWSFierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScienceIlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.comThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.stCuriosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingViewWatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMill
BioPharma Dive Feb 23, 2026

FDA fleshes out new roadmap for testing personalized therapies

FDA fleshes out new roadmap for testing personalized therapies

Original
Body unavailable. Use the original source.